News und Analysen
EQS-News: Abivax appoints Patrick Malloy as Senior Vice President Investor Relations
EQS-News: Abivax secures up to EUR 150M from two structured debt financing transactions
EQS-News: Abivax announces plans to conduct registered public offering in the United States
ABIVAX: NOTICE TO HOLDERS OF BONDS CONVERTIBLE AND/OR EXCHANGEABLE INTO NEW AND/OR EXISTING SHARES (OCEANE) WITH A NOMINAL VALUE OF EUR 24,999,975.99
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA: Half-year results 2023 of Sartorius Stedim Biotech
Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech completes acquisition of Polyplus
Poxel Announces Upcoming Participation at the H.C. Wainwright 2nd Annual Kidney Conference
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Transgene Receives $15.3 Million from the Sale of Securities Held for Sale
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it has received $15.3
EQS-News: Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors
Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in the UK
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Poxel, winner of the 2023 edition of the I-nov contest
Regulatory News:
POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Poxel Announces the Approval of a Prospectus for the Listing of New Shares on Euronext Paris
Regulatory News:
POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Poxel Announces Results from June 21, 2023 Ordinary Annual and Extraordinary General Meeting
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Sensorion Reports Promising Preliminary Data from SENS-401 Phase 2a Clinical Study
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
EQS-News: Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023
Poxel Announces its Participation at Patient Association Conferences in Adrenoleukodystrophy
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
EQS-News: Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting